There is one clinical trial.
This is a Phase II pilot exploratory study designed to investigate if prophylactic treatment with short term steroids administered to high risk Covid-19 patient might prevent cytokine storm and progression to respiratory failure. High risk is defined based on serologic markers of inflammation that include abnormalities of Interleukin 6 (IL-6), Ferritin , D-dimer, Lactate Dehydrogenase (LDH), as well as lymphopenia and impaired O2 saturation prior to or on the 7th day of first symptom of Covid-19.
Description: Clinical complete response criteria requires all the following: No need for ventilatory support at any point O2 Saturation of >/= 93% by day 14 of therapy Alive by day 28 from registration CT chest with minimal or no evidence of disease by day 28 from registrationMeasure: Clinical complete response criteria Time: 14 days
Description: Clinical Partial Response criteria require that 2 of the following be present by day 14 of therapy: No need for ventilatory support at any point O2 saturation > 93% bay day 14 from registration CT chest stable to improve over baseline by day 28 from registrationMeasure: Clinical Partial Response criteria Time: 14 days
Description: Decrease of at least 25% in anyone of the following markers: IL-6, Ferritin, D-dimer, C reactive protein (CRP) or LDH by day 14 - Improvement of absolute lymphocyte count in those presenting with lymphopenia. Improvement is defined as increase by 25% or more by day 14.Measure: Secondary response criteria Time: 14 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports